drugset / Trial / NCT00437697

Thromboprophylaxis in Critically Ill Patients

NCT00437697

Phase 4 Terminated 90 enrolled Medical University of Vienna
RandomizedParallel-groupOpen-labelPrevention

Summary

Intensive care patients are at high risk to develop deep venous thrombosis and pulmonary embolism. Despite anticoagulation with heparin 7% of ICU patients suffer from this serious complication. Optimal regimens for prevention of VTE have been established in medical patients only and are not known for ICU patients. It was therefore the aim of this study to compare the bioavailability of a low molecular weight heparin in ICU patients and in medical patients. Furthermore, we looked wether a 50% dose increase resulted in better bioavailability of this drug.

Timeline

Start
2003-04
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 5000 iu Subcutaneous
Subject Dalteparin sodium Other / unclassified 7500 iu Subcutaneous